Identification of gentamicin-binding proteins in the inner ear

内耳庆大霉素结合蛋白的鉴定

• 批准号: 7459659
• 负责人: Takatoshi Karasawa
• 金额: $ 15.4万
• 依托单位: OREGON HEALTH & SCIENCE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-08-15 至 2011-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7459659
• 关键词: Acute Disease; Acute Kidney Failure; Affect; Aminoglycoside Antibiotics; Aminoglycosides; Antibodies; Attenuated; Auditory; Bacterial Infections; Binding; Binding Proteins; Biochemical; Biological Assay; Bos taurus; Cattle; Cell Death; Cell Line; Cells; Chemistry; Chronic; Condition; Confocal Microscopy; Coomassie blue; Cytoskeleton; Disease; Distal; Equilibrium; Escherichia coli; Family suidae; Future; Gene Expression; Gentamicins; Goals; Hair Cells; Immunohistochemistry; In Vitro; Individual; Infant; Kidney; Labyrinth; Lead; Life; Localized; Mammalian Cell; Mass Spectrum Analysis; Microsomes; Molecular Chaperones; Nephrotoxic; Organ of Corti; Pathogenesis; Patients; Pattern; Pharmaceutical Preparations; Physiological; Play; Predisposition; Premature Infant; Prevention; Prophylactic treatment; Proteins; Proximal Kidney Tubules; Recombinant Proteins; Relative (related person); Reporting; Research; Risk; Role; Sensory Hair; Sepharose; Sodium Dodecyl Sulfate-PAGE; Staining method; Stains; Techniques; Tissues; Toxic effect; Wounds and Injuries; aminoglycoside-induced ototoxicity; calreticulin; cell type; cytotoxicity; deafness; immunocytochemistry; in vivo; insight; nephrotoxicity; novel; ototoxicity; prevent; protein E; protein expression; protein function

DESCRIPTION (provided by applicant): Aminoglycoside antibiotics like gentamicin are essential for battling life-threatening bacterial infections. Aminoglycosides also cause permanent deafness/balance disorders and nephrotoxicity in more than 120,000 individuals each year in the US, particularly in infants and premature babies. The long-term goal of this research is to prevent aminoglycoside-induced ototoxicity by modulating the functions of gentamicin-binding proteins crucial for ototoxicity, to preserve auditory function. In this proposal, we seek to identify gentamicin-binding proteins, and determine their distribution in the inner ear. We hypothesize that there are gentamicin-binding proteins in the inner ear, and that these proteins retain gentamicin in specific types of cells, contributing to cytotoxicity in vitro and pathogenesis in vivo. The specific aims of this project are: First, to identify gentamicin-binding proteins specific in kidney proximal tubule and cochlear cells. We will use a gentamicin-agarose pull-down assay and SDS-polyacrylamide gel electrophoresis to isolate such proteins from kidney proximal tubule and cochlear cell lines, and determine their identity using mass spectrometry (Aim 1). Second, to determine the distribution of gentamicin-binding proteins, including HSP73 and calreticulin, in the inner ear by immunocytochemistry and confocal microscopy. We will also determine if these proteins are co-localized with systemically-administered gentamicin, using fluorescently-tagged gentamicin or untagged gentamicin localized by gentamicin immunocytochemistry (Aim 2). If we can identify gentamicin-binding proteins that sequester the drug within cells that then induce cytotoxicity, we can develop new strategies to inhibit their interactions, and attenuate drug retention. Alternatively, if gentamicin-binding inhibits the functions of these proteins, we could use pharmacological activators of these proteins to overcome gentamicin-induced inhibition. Future studies will determine if gentamicin inhibits their interactions with physiological binding molecules/proteins, and if expression levels of gentamicin-binding proteins change during sustained treatment with gentamicin. Identification of gentamicin-binding proteins and their intracellular mechanisms that gentamicin interferes with to initiate cell death will provide new insight for clinicians to screen patients for pre-existing conditions and medications that elevate the risk of aminoglycoside toxicity and deafness. Identification of gentamicin-binding proteins that play a major role in gentamicin- induced ototoxicity is crucial in understanding how gentamicin induces ototoxicity and deafness. The proposed research will enable us to develop strategies to prevent interactions between gentamicin and gentamicin-binding proteins, and to overcome gentamicin-induced inhibition by pharmacologically activating the proteins. These strategies will lead to ototoxicity and deafness prevention.

描述（由申请人提供）：氨基糖苷类抗生素，如庆大霉素，对对抗危及生命的细菌感染至关重要。在美国，氨基糖苷类药物每年还会导致超过12万人永久性耳聋/平衡障碍和肾毒性，尤其是婴儿和早产儿。本研究的长期目标是通过调节对耳毒性至关重要的庆大霉素结合蛋白的功能来预防氨基糖苷诱导的耳毒性，以保护听觉功能。在这个提议中，我们试图鉴定庆大霉素结合蛋白，并确定它们在内耳中的分布。我们假设内耳中存在庆大霉素结合蛋白，这些蛋白将庆大霉素保留在特定类型的细胞中，有助于体外细胞毒性和体内发病机制。该项目的具体目的是：首先，鉴定肾近端小管和耳蜗细胞特异性庆大霉素结合蛋白。我们将使用庆大霉素琼脂糖下拉试验和sds -聚丙烯酰胺凝胶电泳从肾近端小管和耳蜗细胞系中分离出这些蛋白质，并使用质谱法确定它们的身份（目的1）。其次，通过免疫细胞化学和共聚焦显微镜检测庆大霉素结合蛋白（包括HSP73和钙网蛋白）在内耳中的分布。我们还将确定这些蛋白是否与系统给药的庆大霉素共定位，使用荧光标记庆大霉素或通过庆大霉素免疫细胞化学定位的未标记庆大霉素（目的2）。如果我们能识别庆大霉素结合蛋白，这些蛋白将药物隔离在细胞内，然后诱导细胞毒性，我们就能开发出新的策略来抑制它们的相互作用，并减少药物潴留。或者，如果庆大霉素结合抑制了这些蛋白质的功能，我们可以使用这些蛋白质的药理激活剂来克服庆大霉素诱导的抑制。未来的研究将确定庆大霉素是否会抑制它们与生理结合分子/蛋白质的相互作用，以及庆大霉素结合蛋白的表达水平是否会在持续使用庆大霉素的过程中发生变化。鉴定庆大霉素结合蛋白及其细胞内机制，庆大霉素干扰启动细胞死亡，将为临床医生筛查患者先前存在的疾病和增加氨基糖苷毒性和耳聋风险的药物提供新的见解。鉴定庆大霉素结合蛋白在庆大霉素诱导的耳毒性中起主要作用，对于了解庆大霉素如何诱导耳毒性和耳聋至关重要。这项研究将使我们能够制定策略来防止庆大霉素和庆大霉素结合蛋白之间的相互作用，并通过药理激活蛋白质来克服庆大霉素诱导的抑制作用。这些策略将导致耳毒性和耳聋的预防。